Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults
NCT02416453Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2015
- Primary completion
- Jan 2018
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of zabdeno, Mvabea in Ebola virus disease (EVD), sponsored by Janssen Pharmaceutical. Started Jun 2015; status: completed.
02
Drugs
zabdenoMvabea
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02416453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02416453.